Skip to Content
Merck
All Photos(1)

Documents

361275

Sigma-Aldrich

3′-Deoxy-3′-fluorothymidine

97%

Synonym(s):

3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H13FN2O4
CAS Number:
25526-93-6
Molecular Weight:
244.22
MDL number:
MFCD00056058
UNSPSC Code:
41106305
PubChem Substance ID:
24862180
NACRES:
NA.22

Assay

97%

form

solid

mp

176-178 °C (lit.)

storage temp.

2-8°C

SMILES string

CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

InChI key

UXCAQJAQSWSNPQ-XLPZGREQSA-N

Gene Information

human ... TK2(7084)

Looking for similar products? Visit Product Comparison Guide

Application

Promising antiviral agent possessing activity similar to other 3′-deoxy-3′-substituted thymidines.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P Herdewijn et al.
Journal of medicinal chemistry, 30(8), 1270-1278 (1987-08-01)
A series of 2',3'-unsaturated and 3'-substituted 2',3'-dideoxynucleoside analogues of purines and pyrimidines have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV). The 2',3'-unsaturated analogues of 2',3'-dideoxycytidine (ddeCyd) and 2',3'-dideoxythymidine (ddeThd), 3'-azido-2',3'-dideoxythymidine (AzddThd), 3'-fluoro-2',3'-dideoxythymidine, 2',3'-dideoxycytidine (ddCyd)
Julian L Goggi et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(9), 1630-1636 (2013-08-03)
Successful antiangiogenic therapies have been developed for the treatment of various cancers, but not all patients respond. Therefore, the early determination of therapy efficacy is essential for patient management. This study was done to evaluate the utility of various PET
Yuka Yamamoto et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(12), 1911-1915 (2012-10-20)
We evaluated 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake in patients with newly diagnosed and recurrent gliomas and correlated the results with tumor grade and proliferative activity. (18)F-FLT PET was investigated retrospectively in 56 patients, including 36 with newly diagnosed gliomas and 20 with
Nicolas Graf et al.
European journal of nuclear medicine and molecular imaging, 40(1), 34-43 (2012-10-12)
Positron emission tomography (PET) with the thymidine analogue [(18)F]fluorothymidine ([(18)F]FLT) has been shown to detect early response to chemotherapy in high-grade lymphoma. In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG)
Eliot T McKinley et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)
Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service